Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes

NCT02998970 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT02998970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02998970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes
Lead sponsor
Unity Health Toronto
Phase
Phase 4
Overall status
Unknown status
Start date
January 31, 2017
Completion date
September 30, 2018
Enrollment
97 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, diabetes